fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Highlights from BSH 2019

Written by | 1 May 2019

The 2019 annual meeting of the BSH showcased the best UK research with over 36 sessions covering a range of important issues related to the treatment of haematological… read more.

ASH 2018: TOURMALINE-MM3 study

Written by | 25 Jan 2019

Article written by Maria Dalby. Interview by Hannah Chatfield. Professor Kwee Yong (London, UK), Dr Martin Kaiser (London, UK) and Professor Gareth Morgan (Arkansas, USA) discuss the results from the Tourmaline-MM3 study and… read more.

EHA 2018: Molecular profiling in multiple myeloma 

Written by | 3 Aug 2018

In addition to clinical segmentation of MM patients as young or elderly and fit or frail, genetic factors convey important prognostic information and should be taken into account… read more.

EHA 2018: Immunotherapy in MM: why, when and how?

Written by | 24 Jun 2018

The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.

EHA 2018: The Issue of Frailty in MM

Written by | 24 Jun 2018

When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.

EHA 2018: Preferred treatment combinations and sequencing in transplant eligible and elderly MM patients

Written by | 24 Jun 2018

The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.

BSH 2018: Personalised cancer vaccines and cellular therapy: changing the treatment paradigm for haematological malignancies

Written by | 11 May 2018

Dendritic cells (DC) are known to play an important role in the initiation of primary immune responses. In cancer, deficient DCs contribute to tumour-associated immune tolerance. Functionally active… read more.

BSH 2018: Stratified medicine – using genomic analysis to deliver therapy in high-risk myeloma

Written by | 11 May 2018

Dr Martin Kaiser (London) discusses recent work from the UK on identifying robust markers and how clinical decisions can be made according to the biology of the disease. Advances… read more.

Real-world data shows details beyond the clinical trials

Written by | 21 Feb 2018

Professor Paul G. Richardson MD (R.J. Corman Professor, Medicine, Harvard Medical School, Boston, USA) and Dr Karthik Ramasamy (Oxford Oncology and Haematology Centre) discuss important learnings from real-world… read more.

More ASH Highlights (Myeloma)

Written by | 21 Feb 2018

There were lots of updates from various studies in myeloma at ASH 2017. Above, Professor Sagar Lonial (Emory University School of Medicine, Atlanta, GA) discusses data presented showing… read more.

UK research in the spotlight at ASH

Written by | 16 Feb 2018

The chair of the UK Myeloma Research Alliance, Professor Gordon Cook (Leeds Teaching Hospitals Trust) highlights some of the data presented from the UK, including data from the… read more.

ASH Highlights (Myeloma)

Written by | 13 Feb 2018

As usual, there was a lot of new data in at ASH 2017 in myeloma. Above Professor S Vincent Rajkumar (Mayo Clinic, Rochester, USA) gives a great overview of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.